End Brain Cancer Initiative - the Chris Elliott Fund

Investigational product Immune12 is a proprietary complex biologic derived from specific marine-sourced ingredients. Biologics are medications that come from organic life.

A phase 2 clinical trial of Immune12 in Australia (ANZCTR) is currently recruiting glioblastoma (GBM) brain cancer patients. The trial is led by Chief Principal Investigator Dr. Janet Schloss, PhD, ND, and plans to enroll approximately 60 participants.

To learn more about available clinical trial and treatment options, including Immune12, fill out an interest form here: https://monkeylink.co/18c24b. You can also contact EBCI's Clinical Research Coordinator/Patient Navigator directly by emailing [email protected] or calling/texting 425-436-8688.

Belay Diagnostics Summit is a CSF liquid biopsy that gives doctors molecular information about your tumor from a standard spinal tap. That information can help confirm a diagnosis, choose treatments, and track whether treatment is working without a brain biopsy.

A new peer-reviewed study from UT Southwestern Medical Center, published in Cancers, evaluated Summit in 120 patients with CNS cancer. Summit helped guide clinical decisions in 93 percent of cases. Read more here: https://monkeylink.co/ede596

To learn more about Belay Diagnostics, fill out the interest form at Belay Diagnostics - End Brain Cancer https://monkeylink.co/43b645.